Literature DB >> 21545481

The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase.

Nimish N Vachharajani1, Ralph H Raymond, Wen-Chyi Shyu, Bruce C Stouffer, David W Boulton.   

Abstract

AIMS: To investigate the influence of age and gender on the intravenous pharmacokinetics and pharmacodynamics of the plasminogen activator, lanoteplase.
METHODS: Forty healthy subjects (10 each of young males, elderly males, young females and elderly females) received a single bolus 10 kU kg(-1) intravenous dose of lanoteplase. Plasma from blood serially collected for 24 h post-dose was analyzed for lanoteplase (antigen), fibrinogen, plasminogen and α2-antiplasmin concentrations, plasma plasminogen activation activity (PPAA) and rapid plasminogen activator inhibitor (PAI-1).
RESULTS: Lanoteplase mean total systemic clearance (CL(t)) values ranged from 1.9 to 2.8 l h(-1) and mean steady-state volume of distribution (V(ss)) values ranged from 12.3 to 15.6 l. Age-by-gender interactions were observed for lanoteplase CL(t) (P= 0.04), but no differences were observed for V(ss) or elimination half-life. Elderly females had a 27% lower mean CL(t) than young females (95% CI for the difference 0.17, 1.27 l h(-1)) and 32% lower CL(t) than elderly males (95% CI for the difference 0.15, 1.65 l h(-1)). PPAA AUC/dose values did not show an age-by-gender interaction. Haemostasis parameters indicated only a slight degree of systemic plasminogen activation.
CONCLUSIONS: Elderly females had a lower mean lanoteplase CL(t) than elderly males and young females. However, no difference was observed between young and elderly females for the AUC/dose of PPAA. In addition, there were no age-related or gender-related differences observed in the other pharmacodynamic parameters measured.
© 2011 Bristol-Myers Squibb, Co. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21545481      PMCID: PMC3243012          DOI: 10.1111/j.1365-2125.2011.04003.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

Review 1.  Advances in the medical management of acute coronary syndromes.

Authors:  C P Cannon
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.

Authors:  D V Sakharov; M Barrertt-Bergshoeff; R T Hekkenberg; D C Rijken
Journal:  Thromb Haemost       Date:  1999-04       Impact factor: 5.249

3.  Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.

Authors:  H K Gold; R C Leinbach; H D Garabedian; T Yasuda; J A Johns; E B Grossbard; I Palacios; D Collen
Journal:  Circulation       Date:  1986-02       Impact factor: 29.690

4.  Allergic reactions to streptokinase consistent with anaphylactic or antigen-antibody complex-mediated damage.

Authors:  K G McGrath; B Zeffren; J Alexander; K Kaplan; R Patterson
Journal:  J Allergy Clin Immunol       Date:  1985-09       Impact factor: 10.793

5.  1983 metropolitan height and weight tables.

Authors: 
Journal:  Stat Bull Metrop Life Found       Date:  1983 Jan-Jun

6.  A sensitive assay for tissue plasminogen activator.

Authors:  M Rånby; B Norrman; P Wallén
Journal:  Thromb Res       Date:  1982-09-15       Impact factor: 3.944

Review 7.  Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA).

Authors:  T K Nordt; M Moser; B Kohler; W Kübler; C Bode
Journal:  Thromb Haemost       Date:  1999-09       Impact factor: 5.249

8.  Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).

Authors: 
Journal:  Lancet       Date:  1986-02-22       Impact factor: 79.321

9.  Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.

Authors:  John B Kostis; Randy C Dockens; Udho Thadani; Vasnath Bethala; Carl Pepine; Wayne Leimbach; Nimish Vachharajani; Ralph H Raymond; Bruce C Stouffer; Lee K Tay; Wen Chyi Shyu; Wei-chi Liao
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.

Authors:  M Moroi; N Aoki
Journal:  J Biol Chem       Date:  1976-10-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.